Literature DB >> 23914263

Oncologic outcomes following radical prostatectomy in the active surveillance era.

Alyssa S Louis1, Robin Kalnin, Manjula Maganti, Melania Pintilie, Andrew G Matthew, Antonio Finelli, Alexandre R Zlotta, Neil Fleshner, Girish Kulkarni, Robert Hamilton, Michael Jewett, Michael Robinette, Shabbir M H Alibhai, John Trachtenberg.   

Abstract

OBJECTIVE: In this study, we examine the oncologic outcomes of men with low, intermediate and high preoperative risk for prostate cancer treated with radical prostatectomy prior to and during the active surveillance era.
METHODS: We analyzed records from patients who underwent radical prostatectomy at our Canadian tertiary care facility from 2000 to 2012. Patients were stratified by D'Amico preoperative risk category and by year of treatment. Biochemical recurrence-free survival was estimated using the Kaplan-Meier method.
RESULTS: We included 2643 consecutive patients in our analysis. The proportion of men with low-risk disease undergoing radical prostatectomy decreased from 2007 onwards coincident with the implementation of an active surveillance strategy in our institution. Men with low-risk and high-risk disease showed significantly worse biochemical outcomes from 2007 to 2012 compared to 2000 to 2006 (p < 0.05), while men with intermediate-risk prostate cancer showed no significant differences (p = 0.27). Within the low-risk cohort, the later treatment group displayed significantly lower age, pre-treatment prostate specific antigen and tumour volume and significantly higher testosterone and body mass index.
CONCLUSIONS: The time period corresponding with the implementation of active surveillance at our institution corresponded with significant deterioration of biochemical outcomes in the low- and high-risk groups. This suggests that the men with most favourable disease deferred treatment, whereas men with worse preoperative disease characteristics were increasingly treated with radical prostatectomy in the past 6 years perhaps to their benefit.

Entities:  

Year:  2013        PMID: 23914263      PMCID: PMC3713145          DOI: 10.5489/cuaj.1404

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  22 in total

1.  Pathologic findings in radical prostatectomy specimens from patients eligible for active surveillance with highly selective criteria: a multicenter study.

Authors:  Jean-Baptiste Beauval; Guillaume Ploussard; Michel Soulié; Christian Pfister; Simon Van Agt; Sébastien Vincendeau; Sébastien Larue; Jérome Rigaud; Nicolas Gaschignard; Morgan Rouprêt; Sarah Drouin; Mickael Peyromaure; Jean Alexandre Long; Francois Iborra; Guy Vallancien; Francois Rozet; Laurent Salomon
Journal:  Urology       Date:  2012-07-07       Impact factor: 2.649

Review 2.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.

Authors:  Jonathan I Epstein; William C Allsbrook; Mahul B Amin; Lars L Egevad
Journal:  Am J Surg Pathol       Date:  2005-09       Impact factor: 6.394

3.  Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly.

Authors:  Roderick C N van den Bergh; Stijn Roemeling; Monique J Roobol; Gunnar Aus; Jonas Hugosson; Antti S Rannikko; Teuvo L Tammela; Chris H Bangma; Fritz H Schröder
Journal:  Eur Urol       Date:  2008-09-17       Impact factor: 20.096

4.  Prostate cancer and the Will Rogers phenomenon.

Authors:  Peter C Albertsen; James A Hanley; George H Barrows; David F Penson; Pam D H Kowalczyk; M Melinda Sanders; Judith Fine
Journal:  J Natl Cancer Inst       Date:  2005-09-07       Impact factor: 13.506

5.  Long Term-Survival after Radical Prostatectomy for men with High Gleason Sum.

Authors:  Phillip M Pierorazio; Thomas J Guzzo; Misop Han; Trinity J Bivalacqua; Jonathan I Epstein; Edward M Schaeffer; Mark Schoenberg; Patrick C Walsh; Alan W Partin
Journal:  Urology       Date:  2010-09-01       Impact factor: 2.649

6.  Early prostate cancer--which treatment do men prefer and why?

Authors:  Carmel N Anandadas; Noel W Clarke; Susan E Davidson; Patrick H O'Reilly; John P Logue; Lynne Gilmore; Ric Swindell; Richard J Brough; Guy D Wemyss-Holden; Maurice W Lau; Pradip M Javle; Vijay A C Ramani; James P Wylie; Gerald N Collins; Stephen Brown; Richard A Cowan
Journal:  BJU Int       Date:  2010-11-17       Impact factor: 5.588

7.  Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.

Authors:  Jeffrey J Tosoian; Bruce J Trock; Patricia Landis; Zhaoyong Feng; Jonathan I Epstein; Alan W Partin; Patrick C Walsh; H Ballentine Carter
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

8.  Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.

Authors:  Kenneth Westover; Ming-Hui Chen; Judd Moul; Cary Robertson; Thomas Polascik; Daniel Dosoretz; Michael Katin; Sharon Salenius; Anthony V D'Amico
Journal:  BJU Int       Date:  2012-04-30       Impact factor: 5.588

9.  Treatment decision-making for localized prostate cancer: what younger men choose and why.

Authors:  Abhinav Sidana; David J Hernandez; Zhaoyong Feng; Alan W Partin; Bruce J Trock; Surajit Saha; Jonathan I Epstein
Journal:  Prostate       Date:  2011-04-25       Impact factor: 4.104

10.  Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy.

Authors:  Stephen A Boorjian; R Jeffrey Karnes; Laureano J Rangel; Eric J Bergstralh; Michael L Blute
Journal:  J Urol       Date:  2008-03-04       Impact factor: 7.450

View more
  6 in total

Review 1.  Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.

Authors:  Jeffrey J Tosoian; Stacy Loeb; Jonathan I Epstein; Baris Turkbey; Peter L Choyke; Edward M Schaeffer
Journal:  Am Soc Clin Oncol Educ Book       Date:  2016

Review 2.  Active surveillance for prostate cancer: current evidence and contemporary state of practice.

Authors:  Jeffrey J Tosoian; H Ballentine Carter; Abbey Lepor; Stacy Loeb
Journal:  Nat Rev Urol       Date:  2016-03-08       Impact factor: 14.432

Review 3.  Active surveillance for prostate cancer: selection criteria, guidelines, and outcomes.

Authors:  Colton H Walker; Kathryn A Marchetti; Udit Singhal; Todd M Morgan
Journal:  World J Urol       Date:  2021-03-02       Impact factor: 4.226

Review 4.  Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices.

Authors:  Netty Kinsella; Jozien Helleman; Sophie Bruinsma; Sigrid Carlsson; Declan Cahill; Christian Brown; Mieke Van Hemelrijck
Journal:  Transl Androl Urol       Date:  2018-02

Review 5.  Stereotactic Body Radiotherapy: Hitting Harder, Faster, and Smarter in High-Risk Prostate Cancer.

Authors:  Rohann J M Correa; Andrew Loblaw
Journal:  Front Oncol       Date:  2022-07-07       Impact factor: 5.738

6.  Multiparametric Magnetic Resonance Imaging for Active Surveillance of Prostate Cancer.

Authors:  Julie Y An; Abhinav Sidana; Peter L Choyke; Bradford J. Wood; Peter A Pinto; İsmail Barış Türkbey
Journal:  Balkan Med J       Date:  2017-09-29       Impact factor: 2.021

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.